In Depth 30 Oct 2018 Shuttles, Bubbles and Ultrasound: Crossing the Blood–Brain Barrier What do shuttles, bubbles and ultrasound have in common? They are all methods that can all be used to target the blood–brain barrier and make treating brain diseases such as cancer and Alzheimer’s easier. The blood–brain barrier is the gatekeeper to the brain. This highly selective protective sheath regulates the flow of substances in and […] October 30, 2018 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2018 Fish Oils Finally Reel in Positive Results for Cardiovascular Disease Purified fish oil can reduce patients’ risks for adverse cardiovascular events by 25%, according to US-Irish Biotech Amarin’s Phase III trial results. The treatment, called Vascepa, significantly reduced the risk of strokes, heart attacks, and death. It also had a good safety profile in the over 8,000 enrolled patients, who were already taking statins. These […] September 26, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 25 Sep 2018 24-Hour Blood Pressure Bracelet Could Combat Hypertension For those with blood pressure problems who hate blood pressure cuffs, hope is here. Swiss biotech aktiia has raised €3.6M to market a medical bracelet that could monitor your blood pressure 24/7. “Think of aktiia as the first medical device to measure blood pressure for long periods of time … that does not influence your […] September 25, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2018 Stem Cells Could Help Patients Recover From Heart Attacks Viscofan BioEngineering has a green light in Spain to start clinical testing for its stem cell technology in patients with weakened heart muscles after a heart attack. While Viscofan BioEngineering’s main focus is on making sausage casings out of collagen, its technology could also help patients with weak heart muscles after suffering from a heart […] July 4, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 18 Jun 2018 Swiss Biotech Tackles Brain Artery Constriction Caused by Hemorrhage Idorsia will start a Phase III trial to study the efficacy of its drug in treating the constriction of arteries in the brain caused by release of chemicals linked to a previous bleed in this area. The Swiss biotech Idorsia will test the efficacy of its drug, clazosentan, for treating patients whose brain arteries have […] June 18, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2018 World’s First Gene Therapy Developer Raises $128M for Hemophilia and Huntington’s uniQure has raised a substantial public offering on the NASDAQ. The funding could help the Dutch biotech advance two new gene therapies after the withdrawal of its first treatment. Amsterdam-based uniQure has raised an ambitious $128M (€107M) in a public offering at the beginning of next week. The Dutch biotech develops gene therapies for hemophilia and Huntington’s disease, for […] May 3, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2018 A New Drug for Atrial Fibrillation Starts Human Testing in Europe Update (14/03/2018): Acesion Pharma has started a Phase I clinical trial at the Centre for Human Drug Research (CHDR) in the Netherlands. The trial will test AP30663, a treatment for atrial fibrillation that the company believes has the potential to work better than every option currently available. Originally published on 2/8/2018 The Danish biotech Acesion Pharma […] March 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 1 Mar 2018 Just a Single Dose of this Drug Boosts the Survival of Heart Failure Patients Berlin Cures’ drug fights off self-reactive antibodies that are associated with 80% of heart failure cases to improve heart function and patient survival. Berlin Cures was founded in 2014 to make use of research being carried out at Charité Medical University and the Max-Delbrueck-Center in Berlin. The biotech has achieved promising clinical data that suggests its first […] March 1, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2018 Implantation of Carmat’s Artificial Heart Begins in Denmark to Beat Low Enrolment Carmat’s artificial heart is being tested in patients with heart failure. A hospital in Copenhagen will implant the device, which the biotech hopes will boost patient enrolment to its PIVOTAL trial. Carmat has developed the world’s most advanced fully artificial heart, which has been designed for patients suffering from end-stage biventricular heart failure. The biotech has […] February 21, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Startup Scout 26 Jan 2018 This Danish Biotech is Working on Better, Safer Drugs for Cardiac Arrhythmia This week, we’re visiting Acesion Pharma in Copenhagen, a biotech that is developing more effective, safer drugs for atrial fibrillation, the most common form of cardiac arrhythmia. Mission: Since being founded in 2011, Acesion has already caught our attention, being named as one of our top biotechs in Copenhagen. The biotech focuses on the development of […] January 26, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2018 British Biotech Treats First Phase III Patient in its Critical Limb Ischemia Trial Rexgenero has treated the first patient in a Phase III trial investigating REX-001, the biotech’s cell therapy for critical limb ischemia. Rexgenero is a biotech working on regenerative medicine techniques to treat critical limb ischemia (CLI). The condition is characterized by blocked arteries in the lower limbs that can force doctors to amputate. The company has […] January 25, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 18 Jan 2018 First Patient Successfully Implanted with Heart Valve Replacement Device French company Kephalios has successfully implanted a new adjustable device to repair a heart valve defect in a human patient for the first time. The first of five patients in a clinical trial at the Vienna General Hospital has received an implant designed to repair mitral valve regurgitation. This disease causes the mitral valve to not close properly […] January 18, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email